Dose requirement of d-tubocurarine and metocurine used for chronic respiratory paralysis in neonates.
Nondepolarizing muscle relaxants are being used with increasing frequency in neonatal intensive care units. However, information concerning the chronic use of these agents and their dose requirements of d-tubocurarine and metocurine in neonates in whom respiratory paralysis was used as an adjunct to mechanical ventilation. All infants with gestational age greater than or equal to 38 wk demonstrated a dramatic daily increase in dose requirement of metocurine during the initial 8 days. However, infants with gestational age greater than or equal to 33 wk did not demonstrate a statistically significant daily increase in dose requirement. The 4 infants who received metocurine for more than 10 days exhibited a plateau of the dose requirement after 8-10 days. In contrast to the infants receiving metocurine, infants who received d-tubocurarine did not demonstrate a significant change in daily dose requirement. Four infants who received metocurine and four who received d-tubocurarine had acute renal failure and were not included in the above analysis. These infants had a significantly decreased dose requirement compared to the expected dose requirement for infants of comparable gestational age. There was no relationship between the dose requirement and the pH, serum potassium, or the use of aminoglycoside antibiotics.
D004305:Dose-Response Relationship, Drug; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage*; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy*; D014403:Tubocurarine / Q000008:administration & dosage* / Q000031:analogs & derivatives*
D009466:Neuromuscular Blocking Agents; C032943:metocurine; D014403:Tubocurarine